Annual report pursuant to Section 13 and 15(d)

ACCRUED EXPENSES

v3.22.0.1
ACCRUED EXPENSES
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
ACCRUED EXPENSES
10.
ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

 

 

December 31,

 

 

 

2021

 

 

 

2020

 

 

 

 

 

 

 

 

 

Accrued clinical operations and trials costs

$

 

5,435,464

 

 

 $

 

14,132,842

 

Accrued product development costs

 

 

203,676

 

 

 

 

2,189,047

 

Accrued compensation

 

 

2,715,368

 

 

 

 

4,222,594

 

Accrued other

 

 

1,738,804

 

 

 

 

1,460,949

 

Total

$

 

10,093,312

 

 

 $

 

22,005,432